Laura K. Ferris
Experienced in Congenital Hemidysplasia with Ichthyosiform Erythroderma and Limbs Defects

Dr. Laura K. Ferris

Dermatology | Pediatrics | General Practice
University Of North Carolina At Chapel Hill
410 Market St, Suite 400a, 
Chapel Hill, NC 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Congenital Hemidysplasia with Ichthyosiform Erythroderma and Limbs Defects
University Of North Carolina At Chapel Hill
410 Market St, Suite 400a, 
Chapel Hill, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Laura Ferris is a Dermatologist and an Internal Medicine provider in Chapel Hill, North Carolina. Dr. Ferris is rated as an Experienced provider by MediFind in the treatment of Congenital Hemidysplasia with Ichthyosiform Erythroderma and Limbs Defects. Her top areas of expertise are Psoriasis, Plaque Psoriasis, Melanoma, and Familial Atypical Multiple Mole Melanoma Syndrome.

Her clinical research consists of co-authoring 131 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Dermatology
Pediatrics
General Practice
Licenses
Specialist in PA
Hospital Affiliations
Unc Hospitals
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Gateway Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Geisinger
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
HealthPartners
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Paramount
  • EPO
  • HMO
  • INDEMNITY
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
410 Market St, Suite 400a, Chapel Hill, NC 27516

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Targeting Nociceptors in Hidradenitis Suppurativa
Targeting Nociceptors in Hidradenitis Suppurativa
Enrollment Status: Recruiting
Publish Date: September 15, 2025
Intervention Type: Drug
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
Enrollment Status: Completed
Publish Date: October 01, 2025
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 2/Phase 3
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Completed
Publish Date: August 03, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects With Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects With Active Cutaneous Lupus Erythematosus With or Without Systemic Manifestations
A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects With Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects With Active Cutaneous Lupus Erythematosus With or Without Systemic Manifestations
Enrollment Status: Completed
Publish Date: November 07, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
Enrollment Status: Terminated
Publish Date: March 21, 2023
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Multiple-Dose, Randomized, Placebo-Controlled, Study of LY3462817 or LY3509754 in Patients With Psoriasis
A Multiple-Dose, Randomized, Placebo-Controlled, Study of LY3462817 or LY3509754 in Patients With Psoriasis
Enrollment Status: Terminated
Publish Date: March 15, 2022
Intervention Type: Drug
Study Drugs: LY3462817-IV, LY3462817-SV
Study Phase: Phase 1
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-2
Enrollment Status: Completed
Publish Date: March 30, 2021
Intervention Type: Drug
Study Phase: Phase 3
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: July 28, 2020
Intervention Type: Drug
Study Phase: Phase 4
View 8 Less Clinical Trials

131 Total Publications

Prospective evaluation of an AI-enabled elastic scattering spectroscopy device for triage of patient-identified skin lesions in dermatology clinics.
Prospective evaluation of an AI-enabled elastic scattering spectroscopy device for triage of patient-identified skin lesions in dermatology clinics.
Journal: JAAD international
Published: October 06, 2025
Similar Doctors
Advanced in Congenital Hemidysplasia with Ichthyosiform Erythroderma and Limbs Defects
Dr. Dean S. Morrell
Dermatology
Advanced in Congenital Hemidysplasia with Ichthyosiform Erythroderma and Limbs Defects
Dr. Dean S. Morrell
Dermatology
101 Manning Dr, 
Chapel Hill, NC 
 (1.7 miles away)
919-966-4131
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Dean Morrell is a Dermatologist in Chapel Hill, North Carolina. Dr. Morrell is rated as an Advanced provider by MediFind in the treatment of Congenital Hemidysplasia with Ichthyosiform Erythroderma and Limbs Defects. His top areas of expertise are Molluscum Contagiosum, Acne, Pyoderma Gangrenosum, and Atopic Dermatitis. Dr. Morrell is currently accepting new patients.

Experienced in Congenital Hemidysplasia with Ichthyosiform Erythroderma and Limbs Defects
Dr. Ermal Aliu
Pediatrics | Medical Genetics
Experienced in Congenital Hemidysplasia with Ichthyosiform Erythroderma and Limbs Defects
Dr. Ermal Aliu
Pediatrics | Medical Genetics

Duke Health Integrated Practice Inc

4709 Creekstone Dr, Suite 300, 
Durham, NC 
 (12.4 miles away)
919-684-8111
Languages Spoken:
English
See accepted insurances

Ermal Aliu is a Pediatrics specialist and a Medical Genetics provider in Durham, North Carolina. Dr. Aliu is rated as an Advanced provider by MediFind in the treatment of Congenital Hemidysplasia with Ichthyosiform Erythroderma and Limbs Defects. His top areas of expertise are Phenylketonuria (PKU), Learman Syndrome, Microcephaly, and Symphalangism Distal.

Experienced in Congenital Hemidysplasia with Ichthyosiform Erythroderma and Limbs Defects
Dr. Annette K. Ansong
Pediatric Cardiology | Cardiology | Pediatrics
Experienced in Congenital Hemidysplasia with Ichthyosiform Erythroderma and Limbs Defects
Dr. Annette K. Ansong
Pediatric Cardiology | Cardiology | Pediatrics
Duke University Medical Ctr, Dumc 3090, 
Durham, NC 
 (11.1 miles away)
919-681-2916
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Annette Ansong is a Pediatric Cardiologist and a Cardiologist in Durham, North Carolina. Dr. Ansong is rated as an Experienced provider by MediFind in the treatment of Congenital Hemidysplasia with Ichthyosiform Erythroderma and Limbs Defects. Her top areas of expertise are Interrupted Aortic Arch, Coronary Artery Fistula, Ventricular Septal Defects, and Congenital Heart Disease (CHD). Dr. Ansong is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ferris's expertise for a condition
ConditionClose
View All 103 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile